A5024662180- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Infectious Disease Case Reports and Treatments
- Epigenetics and DNA Methylation
- Multiple and Secondary Primary Cancers
- Urinary Bladder and Prostate Research
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Screening and Detection
- Urinary Tract Infections Management
- Nutrition and Health in Aging
- Ferroptosis and cancer prognosis
- Cholinesterase and Neurodegenerative Diseases
- Urologic and reproductive health conditions
- Metastasis and carcinoma case studies
- Cardiac, Anesthesia and Surgical Outcomes
- Ureteral procedures and complications
- Enhanced Recovery After Surgery
Vienna General Hospital
2017-2025
Medical University of Vienna
2016-2025
Comprehensive Cancer Center Vienna
2017-2025
European Association of Urology
2019-2024
University of Jordan
2019
Karl Landsteiner Society
2017
The University of Texas Southwestern Medical Center
2016
Cornell University
2016
Ospedale di Bolzano
2016
Medical Research Associates
1998
Primary staging of prostate cancer relies on modalities, which are limited. We evaluate simultaneous [68Ga]Ga-PSMA-11 PET (PSMA-PET)/MRI as a new diagnostic method for primary tumor-node-metastasis compared with histology and its impact therapeutic decisions.We investigated 122 patients PSMA-PET/MRI prior to planned radical prostatectomy (RP). endpoint was the accuracy in tumor staging-relevant histology. In addition, multidisciplinary team reassessed initial approach management.PSMA-PET/MRI...
The first aim of this study was to evaluate 68Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA PET) parameters for assessment response 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). second investigate factors associated overall survival (OS). We retrospectively assessed mean standardized uptake values (SUVmean) and total tumor volumes (TTV) on PSMA PET 38 55 mCRPC before after RLT. PSA testing PET/CT(MRI)...
To evaluate the diagnostic performance of [68Ga]Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA-PET) in early detection metastases patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to compare it CT/MRI alone and assess its impact on further therapeutic decisions. We retrospectively assessed 117 consecutive hormone-naïve BCR who had 68Ga-PSMA PET/CT (n = 46) or PET/MRI 71) between May 2014 January 2017....
Objectives To investigate prospectively the clinical utility and influence on decision‐making of Bladder EpiCheck™, a non‐invasive urine test, in surveillance non‐muscle‐invasive bladder cancer ( NMIBC ). Materials Methods Urine samples from 440 patients undergoing for were collected at five centres evaluated using EpiCheck test NCT 02647112). A multivariable nomogram decision‐curve analysis DCA ) used to evaluate impact when routine practice. The was designed exclude recurrent disease....
En bloc transurethral resection of the bladder (eTURB) might improve surgical management non-muscle-invasive cancer (NMIBC) in comparison to conventional TURB (cTURB).
Abstract Prostate cancer (PCa) is a common and fatal type of in men. Metastatic PCa (mPCa) major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN one most frequently deleted genes mPCa. Here we show frequent genomic co-deletion STAT3 liquid biopsies patients with Loss Stat3 Pten -null mouse prostate model leads reduction LKB1/pAMPK simultaneous activation mTOR/CREB, resulting metastatic disease. However, constitutive led high levels suppressed...
Background and objectiveIntermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC) encompasses a broad spectrum of disease, with heterogeneous outcomes in terms disease recurrence progression. The International Bladder Cancer Group (IBCG) recently proposed an updated scoring model for IR substratification that is based on five key risk factors. Our aim was to provide clinical validation the IBCG system NMIBC.MethodsThis international multicenter retrospective study. Patients diagnosed...
To assess the oncological outcomes of patients with high-risk (HR) and very (VHR) non-muscle-invasive bladder cancer (NMIBC) treated upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations from a contemporary European multicentre cohort. We conducted retrospective analysis 1491 diagnosed HR- or VHR-NMIBC database between 2015 2024. Patients were included if they received either RC at least five doses BCG. A 1:1 propensity score matching (PSM) according to clinically...
To compare trends in the use of robot-assisted radical cystectomy (RARC) and changes over time peri-operative outcomes selected North American European centres.We conducted a retrospective evaluation 2401 patients treated with open (ORC) or RARC for bladder cancer at 12 centres America Europe between 2006 2018. We used Kruskal-Wallis chi-squared test to evaluate differences continuous categorical variables.Overall, 49.5% underwent 51.5% ORC. became most commonly performed procedure...
To evaluate the impact of an eight-item surgical checklist (SC) on recurrence-free survival (RFS) patients with non-muscle-invasive bladder cancer (NMIBC) undergoing transurethral resection tumour (TURBT).A group urologists at two tertiary referral centres, expertise in cancer, identified eight critical items that should be performed every high-quality TURBT. An SC was prospectively implemented into clinical practice and operative reports TURBTs before after implementation were reviewed....
Background The use of adjuvant chemotherapy (AC) in pure urothelial carcinoma the bladder is established. Regarding variant histology, there a gap knowledge concerning optimal treatment after radical cystectomy (RC). objective this study was to assess effect AC on overall survival (OS) patients who had carcinoma, with concomitant or another histology. Methods Within National Cancer Data Base, 15,397 underwent RC for nonmetastatic, localized and positive lymph nodes (T2N+) locally advanced...
Abstract Background To assess which parameters of [ 68 Ga]Ga‐PSMA‐11 positron emission tomography (PSMA‐PET) predict response to systemic therapies in metastatic (m) castration‐resistant prostate cancer (CRPC). In addition, investigate these factors are associated with overall survival (OS). Methods We retrospectively assessed the following PSMA‐PET 43 patients before and after for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, SUVpeak....